Page 15 - Pharma Stocks
Torrent Pharma surges 8%, hits record high post March quarter results
Torrent's branded generics business India continues to perform well with focus on curatio acquisition and focus on power brands besides consumer business foray.
 "Torrent Pharma surges 8%, hits record high post March quarter results")
Stock of this pharma company has plunged 80% from its record high level
Shares of Gland Pharma tumbled 19 per cent to hit a new low of Rs 872.10 in Monday's intra-day trade, in an otherwise firm market
 "Stock of this pharma company has plunged 80% from its record high level")
Gland Pharma tanks 20%, hits record low on weak Q4 results
Revenue declined 29% YoY due to lower offtake of the key products in developed as well as domestic markets and due to Production line shut down in Pashamylaram Penems facility due to line upgradation.
 "Gland Pharma tanks 20%, hits record low on weak Q4 results")
This smallcap pharma company has zoomed 44% in 3 days on strong Q4 results
Since February 2, 2023, the stock price of Neuland Labs more-than-doubled or zoomed 116 per cent from level of Rs 1,409.75
 "This smallcap pharma company has zoomed 44% in 3 days on strong Q4 results")
Lupin extends gain, hits 52-wk high post Q4 results; surges 20% in 1 month
Analysts believe the stock is factoring margin recovery and certain niche launches in the US.
 "Lupin extends gain, hits 52-wk high post Q4 results; surges 20% in 1 month")
Dr Reddy's Labs sinks 7% on disappointing Q4 operating performance
In Q4, the company's North America's revenue declined 17 per cent QoQ to Rs 2,530 crore, due to fluctuations in demand for new launches.
 "Dr Reddy's Labs sinks 7% on disappointing Q4 operating performance")
PI Industries derisks biz with lucrative pharma buys; stock up 10.2%
Brokerages have upgraded estimates for firm, expect return ratios to improve
 "PI Industries derisks biz with lucrative pharma buys; stock up 10.2%")
Ipca Labs plunges 16% in two days; hits 3-year low on Unichem stake buy
The acquisition will allow Ipca to re-enter US formulation generic market, however at 2.3x sales, as acquisition cost is expensive, given challenges and uncertainty associated with US market.
 "Ipca Labs plunges 16% in two days; hits 3-year low on Unichem stake buy")
Is Mankind Pharma IPO worth a subscription? Here's what brokerages suggest
In the grey markets, shares of Mankind Pharma enjoyed a premium of Rs 90, which translated to a likely listing price of Rs 1,170 per share on the upper price band
 "Is Mankind Pharma IPO worth a subscription? Here's what brokerages suggest")
Sun Pharma's Mohali facility to pause supplies to the US; stock dips 3%
Although the overall impact could be minimal (being an OSD facility), this may lead to stricter scrutiny for other plants, said ICICI Securities in a note.
 "Sun Pharma's Mohali facility to pause supplies to the US; stock dips 3%")
TTK Healthcare hits 5-year high on delisting plan; zooms 70% in 14 days
The board of directors are scheduled to meet on April 20, 2023 to consider the proposal for voluntary delisting of the equity shares of the company.
 "TTK Healthcare hits 5-year high on delisting plan; zooms 70% in 14 days")
Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's
Eris Life said that the transaction would help augment and expand cosmetic dermatology business of the company through their product offerings
 "Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's")
Alembic Pharma slips 5%; board approves Rs 1,150 cr as impairment charges
This one time impairment impact notwithstanding, we believe this move bodes well for future return ratios and profitability. We expect more impairments in due course, ICICI Securities said in a note.
 "Alembic Pharma slips 5%; board approves Rs 1,150 cr as impairment charges")
Analysts turn cautious on Cipla as US FDA action delays key US launches
Analysts believe that some of the recent observations from the US FDA are critical in nature and could lead to a potential Official Action Indicated (OAI) classification for the Indore plant
 "Analysts turn cautious on Cipla as US FDA action delays key US launches")
This beaten down pharma stock has zoomed over 50% in last 11 trading days
Shares of Dishman Carbogen Amcis zoomed 14 per cent to Rs 124 on the BSE in Tuesday's intra-day trade on the back of heavy volumes
 "This beaten down pharma stock has zoomed over 50% in last 11 trading days")
Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low
Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts
 "Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low")
Cipla dips 7% after Pithampur unit receives 8 USFDA observations
The company said it will work closely with the USFDA and is committed to address these comprehensively within stipulated time.
 "Cipla dips 7% after Pithampur unit receives 8 USFDA observations")
Natco Pharma jumps 4% on filing generic version of oncology drug in US
The drug major filed an abbreviated new drug application (ANDA) for generic versions of Olaparib tablets - 100 mg and 150 mg with the US Food and Drug Administration (USFDA)
 "Natco Pharma jumps 4% on filing generic version of oncology drug in US")
Glenmark Pharma jumps 5% post December quarter earnings
The company reported a 21 per cent surge in Q3 consolidated net at Rs 291 crore.
 "Glenmark Pharma jumps 5% post December quarter earnings")
Sun Pharma nears 52-week high ahead of Q3 results; stock up 7% in a month
In the past one month, Sun Pharma outperformed market as shares surged 7 per cent, as compared to 2.5 per cent decline in the S&P BSE Sensex